Articles

• Search by keyword
• Search by citation

3 result(s) for 'Lecanemab' within Alzheimer's Research & Therapy

1. Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

   Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings

   Citation: Alzheimer's Research & Therapy 2022 14:70

   Content type: Correction Published on: 21 May 2022

   The original article was published in Alzheimer's Research & Therapy 2021 13:80

   • View Full Text
   • View PDF

2. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

   Lecanemab (BAN2401), an IgG1 monoclonal antibody, ... to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer’s disease,...

   Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings

   Citation: Alzheimer's Research & Therapy 2021 13:80

   Content type: Research Published on: 17 April 2021

   The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:70

   • View Full Text
   • View PDF

3. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

   Authors: Jeffrey Cummings, Paul Aisen, Cynthia Lemere, Alireza Atri, Marwan Sabbagh and Stephen Salloway

   Citation: Alzheimer's Research & Therapy 2021 13:98

   Content type: Viewpoint Published on: 10 May 2021

   • View Full Text
   • View PDF